Showing results (951-960 of 1,032) with videos related to

Sort By:
Pageof 104
Pain|September 25, 2012
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendationsSandra D Comer, James P Zacny, Robert H Dworkin, et al.
Pain|April 9, 2016
Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendationsAnn M Taylor, Kristine Phillips, Kushang V Patel, et al.
Pain|April 13, 2012
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendationsRobert H Dworkin, Dennis C Turk, Sarah Peirce-Sandner, et al.
Reviews on Recent Clinical Trials|December 30, 2021
COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient InformationDavide Mauri, Konstantinos Kamposioras, Lampriani Tsali, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Cancer Immunology, Immunotherapy : CII|September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective studyOndřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Pageof 104